| 000 | 01766 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250516070958.0 | ||
| 264 | 0 | _c20130701 | |
| 008 | 201307s 0 0 eng d | ||
| 022 | _a1468-3083 | ||
| 024 | 7 |
_a10.1111/j.1468-3083.2011.04387.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWeller, K | |
| 245 | 0 | 0 |
_aSelected urticaria patients benefit from a referral to tertiary care centres--results of an expert survey. _h[electronic resource] |
| 260 |
_bJournal of the European Academy of Dermatology and Venereology : JEADV _cJan 2013 |
||
| 300 |
_ae8-16 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aChronic Disease |
| 650 | 0 | 4 |
_aCyclosporine _xtherapeutic use |
| 650 | 0 | 4 |
_aDermatology _xstandards |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGermany |
| 650 | 0 | 4 | _aHealth Care Surveys |
| 650 | 0 | 4 |
_aHistamine Antagonists _xtherapeutic use |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIncidence |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPatient Selection |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 |
_aReferral and Consultation _xstatistics & numerical data |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 | _aSurveys and Questionnaires |
| 650 | 0 | 4 | _aTertiary Care Centers |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aUrticaria _xdiagnosis |
| 700 | 1 | _aSchoepke, N | |
| 700 | 1 | _aKrause, K | |
| 700 | 1 | _aArdelean, E | |
| 700 | 1 | _aBräutigam, M | |
| 700 | 1 | _aMaurer, M | |
| 773 | 0 |
_tJournal of the European Academy of Dermatology and Venereology : JEADV _gvol. 27 _gno. 1 _gp. e8-16 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1468-3083.2011.04387.x _zAvailable from publisher's website |
| 999 |
_c21397892 _d21397892 |
||